From seed to TWO IPO's is the objective. The first IPO in NZ, The second, in the US when our SEC Form S-1 is filed. This objective has been structured around (1) the seed / post-seed rounds, (2) a NZD10.6M Series A, (3) a USD5M REG-CF campaign in the US, (4) an IPO / stock exchange (NZX) listing in NZ, (5) a US IPO.
Offer offer of 1,200,00 Common Voting Shares priced at NZD0.50c each to a NZ based "NZX Pathway Group" who will lead Tribal Health Corp to an NZX listing. The first step towards a dual NZ-US listing
This placement of 5M shares priced at NZD1 each has been pre-subscribed by the group parent company, Sanctum Stay Realty Inc. This capital closes the Kerikeri agribiz infrastructure support hub and sees the 1st shipment of 36,000 NHP SKU's with an FOB value of NZD873,600 shipped to the showcase in Florida. where the US retail shelf value is circa USD2.582M.
This capital constructs our GMP standard facility located on the Kerikeri orchard. With high visibility on a busy State Highway, the site will provide excellent publicity for the "Tribal" branded Natural Health Products (NHP) that will be produced at the facility.
Founded as a boutique merchant banking firm, Auckland based TBK Capital Ltd is a NZ Financial Markets Authority licensed financial services advisory firm specializing in debt and equity capital raising.
TBK Capital was one of the early movers in supporting the emergence of NZ tea tree oils from the manuka and kanuka tree as a natural, plant oil therapeutic with application in both Infection Control and the antiseptic/disinfectant sectors of the health market.
John's career in NZ merchant banking started with Securitibank, the country's pioneering merchant banking house whose alumni included Michael Fay and David Richwhite amongst many other pioneers of the country's merchant banking industry.
A CA based SEC licensed Regulation Crowdfunding (REG-CF) intermediary is to conduct the campaign on a US coast to coast coverage basis.
Post closing of the USD5M (Series B) crowdfunding campaign the Company plans to seek a listing on the NZ Stock Exchange ("NZX")
Current modeling indicates the Company will have 24.7M shares on issue upon closing the US campaign. A 2:1 share split prior to any NZX IPO offer would take this to 49.4M shares on issue.
Assuming an NZX placement at NZD2 per share post share split, for any one who wants to do the "maths" the ROI for Series A and B investors is significant.
Copyright © 2023 Tribal Partners Ltd - All Rights Reserved.
Powered by Tribal Health